OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+42.42%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$625M
AUM Growth
+$625M
(+10%)
Cap. Flow
-$91M
Cap. Flow
% of AUM
-14.56%
Top 10 Holdings %
Top 10 Hldgs %
76.62%
Holding
47
New
11
Increased
5
Reduced
12
Closed
13
Top Buys
| 1 |
Structure Therapeutics
GPCR
|
$16.9M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$12.6M |
| 3 |
Immunovant
IMVT
|
$11.5M |
| 4 |
Cytokinetics
CYTK
|
$9.68M |
| 5 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$9.36M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$28.5M |
| 2 |
Roivant Sciences
ROIV
|
$21M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$19.3M |
| 4 |
89bio
ETNB
|
$18.8M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$12.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $168M | 26.88% | 2,806,980 -323,020 | -10% | -$19.3M |
|
|
CBAY
2
DELISTED
Cymabay Therapeutics
CBAY
| $63.2M | 10.1% | 2,673,750 -400,000 | -13% | -$9.45M |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $47.1M | 7.54% | 2,369,000 | – | – |
|
4
Insmed
INSM
$28.8B
| $39.8M | 6.37% | 1,284,000 | – | – |
|
5
Arcus Biosciences
RCUS
$1.13B
| $35.7M | 5.71% | 1,868,000 -100,000 | -5% | -$1.91M |
|
6
BridgeBio Pharma
BBIO
$9.89B
| $28.5M | 4.57% | 706,800 -264,839 | -27% | -$10.7M |
|
7
Celldex Therapeutics
CLDX
$1.47B
| $28.1M | 4.49% | 707,526 -52,372 | -7% | -$2.08M |
|
|
8
Roivant Sciences
ROIV
$8.15B
| $28M | 4.48% | 2,494,000 -1,873,000 | -43% | -$21M |
|
|
ALPN
9
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $23.7M | 3.79% | 1,241,300 +491,300 | +66% | +$9.36M |
|
|
10
Structure Therapeutics
GPCR
$1.11B
| $16.9M | 2.7% | +414,000 | New | +$16.9M |
|
|
CNTA
11
Centessa Pharmaceuticals
CNTA
$2.25B
| $16.4M | 2.62% | 2,060,100 +1,584,500 | +333% | +$12.6M |
|
12
AN2 Therapeutics
ANTX
$30.1M
| $13.6M | 2.18% | 664,575 -203,000 | -23% | -$4.16M |
|
13
Viridian Therapeutics
VRDN
$1.5B
| $13.5M | 2.16% | 620,000 -447,143 | -42% | -$9.74M |
|
|
14
Immunovant
IMVT
$2.56B
| $11.5M | 1.84% | +273,289 | New | +$11.5M |
|
15
Dyne Therapeutics
DYN
$1.92B
| $10.5M | 1.69% | 792,945 +100,000 | +14% | +$1.33M |
|
|
16
Cytokinetics
CYTK
$4.23B
| $9.68M | 1.55% | +116,000 | New | +$9.68M |
|
17
Annexon
ANNX
$226M
| $9.31M | 1.49% | 2,050,000 | – | – |
|
|
JBIO
18
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $9.14M | 1.46% | 403,685 -93,685 | -19% | -$2.12M |
|
19
Gossamer Bio
GOSS
$562M
| $8.38M | 1.34% | 9,187,883 +1,000,000 | +12% | +$913K |
|
20
RAPT Therapeutics
RAPT
$188M
| $7.26M | 1.16% | +292,000 | New | +$7.26M |
|
|
CBIO
21
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $7.08M | 1.13% | 3,000,000 | – | – |
|
|
GRCL
22
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $5.99M | 0.96% | +596,611 | New | +$5.99M |
|
23
Dianthus Therapeutics
DNTH
$759M
| $5.76M | 0.92% | 554,000 +74,000 | +15% | +$770K |
|
|
OKUR
24
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $3.6M | 0.58% | 2,250,000 -29,870 | -1% | -$47.8K |
|
25
Jasper Therapeutics
JSPR
$45.5M
| $3.53M | 0.56% | 4,468,114 | – | – |
|